Tempus ECG-AF vs Sleepiz One+

Sleepiz One+ is designed for ease of installation and use, requiring less than 3 minutes for setup and offering contactless monitoring at home, which users find convenient and less disruptive than in-clinic monitoring. Tempus ECG-AF, while integrated into healthcare facility systems, is a software solution that analyzes existing ECG recordings, implying a more clinical, less direct patient interaction regarding usability.

Sleepiz One+ offers continuous, contactless remote patient monitoring of respiration and heart rate, along with sleep apnea screening, providing comprehensive insights into physiological statuses and supporting timely interventions for chronic conditions. Tempus ECG-AF identifies patients at increased risk of developing AF within 12 months, which is valuable for early detection, but its sensitivity and positive predictive value are lower (31% and 19% respectively) compared to Sleepiz One+'s reported accuracy for vital signs (99% for breathing rate, 96% for heart rate).

Sleepiz One+ provides clear pricing for direct-to-consumer sleep apnea screening packages (starting at CHF 129) and explicitly states CPT codes for remote patient monitoring reimbursement, allowing for 16 out of 30 days of measurements for billing purposes. Tempus ECG-AF requires contacting the vendor for pricing, though it does mention CMS reimbursement availability with a Medicare rate of $128.90, effective January 1, 2025, and a self-pay price of $295 for other tests, but not specifically for ECG-AF.

Tempus ECG-AF is a software solution integrated into healthcare facility systems and is compatible with FDA-authorized resting 12-lead ECGs from major manufacturers like GE Medical Systems and Philips Medical Systems, indicating a strong readiness for enterprise-level deployment within existing clinical workflows. Sleepiz One+ is a device that can be deployed in various healthcare settings, including hospitals, skilled nursing facilities, and assisted living, and offers a multi-resident dashboard, but its primary deployment as a bedside device for individual patient monitoring might require more extensive integration efforts for large-scale enterprise-wide data flow.

Sleepiz One+ utilizes contactless radar technology for remote patient monitoring, offering a novel and less intrusive approach to collecting biometric data and vital signs, including sleep apnea screening, which represents a significant innovation in patient comfort and data acquisition. Tempus ECG-AF, while employing AI for ECG analysis to predict AF risk, builds upon existing 12-lead ECG technology, making its innovation more incremental in the method of analysis rather than the mode of data collection.

Both companies offer clear channels for support. Tempus provides customer service via phone and email, along with a policy center and document library. Sleepiz offers email and phone support, detailed instructions for use, and addresses data protection and technical issues in its support documentation. Without specific comparative metrics on response times, comprehensiveness of documentation, or user satisfaction with support, it is difficult to definitively declare a winner.